Everybody Scream, the new album from Florence + The Machine, tops this week’s fan-voted music poll.
Music fans voted in a poll published Friday (Oct. 31) on Billboard, choosing Florence Welch’s latest work as their favorite new…

Everybody Scream, the new album from Florence + The Machine, tops this week’s fan-voted music poll.
Music fans voted in a poll published Friday (Oct. 31) on Billboard, choosing Florence Welch’s latest work as their favorite new…

Jannik Sinner won the Paris Masters for the first time by defeating Felix Auger-Aliassime 6-4, 7-6 (7/4) on Sunday as the four-time Grand Slam champion reclaimed his position atop the world rankings.
The Barron’s news department was not involved…

The latest Android flagship killers have just launched—but the U.S. is being left out of the party. These new phones are powered by the new Snapdragon 8 Elite Gen 5 chip, along with other top-tier specs, and they’re coming in at surprisingly…

Tracking your fitness and health shouldn’t feel like a chore that requires constant charging or complicated setup: You need a device that actually keeps up with your daily routine without dying halfway through the week, one that gives…

A historic drought in the country has culminated in a ‘100 percent drop in precipitation’ in the Tehran region.
Published On 2 Nov 2025
The main source of drinking water for residents of…

KNOXVILLE, Tenn. — Tennessee has dismissed senior guard Ruby Whitehorn from the eighth-ranked Lady Vols, with women’s basketball coach Kim Caldwell saying Sunday that it was her responsibility to protect the program’s high standards.
“In light of…

Abhotel (TSE:6565) posted a net profit margin of 24.6% for the year, up from 23.4% last year, with earnings growing 17.9% year-over-year. Over the past five years, annual earnings growth averaged 42.7%. Shares currently trade at ¥1,751, just above their estimated fair value of ¥1,745.32. The stock’s valuation remains favorable compared to the broader Japanese hospitality industry’s high price-to-earnings ratios.
See our full analysis for Abhotel.
The next section will put these headline results side by side with the leading narratives in the market. This will highlight where expectations were met and where surprises may drive new investor debate.
Curious how numbers become stories that shape markets? Explore Community Narratives
Abhotel reported a five-year average annual earnings growth of 42.7%, which far surpasses typical industry rates. However, the most recent year’s growth came in at 17.9%, showing a notable moderation versus its longer-term trend.
The prevailing market view weighs this shift in momentum. Investors are watching closely to see if this year’s deceleration is a simple pause or hints at a maturing growth story.
While such high multi-year earnings expansion strongly supports the argument that Abhotel still holds upside potential in a recovering travel market, the drop from the five-year average to the latest 17.9% figure creates tension about whether outsized growth is sustainable as the company scales.
Robust expansion has set a high bar, and demand tailwinds offer support, yet the sharp slowdown in this year’s growth will rightly focus attention on the company’s ability to drive further margin gains or unlock new segment performance.
Net profit margin increased to 24.6% in the latest period, a meaningful lift from last year’s 23.4%, as the company bucked stagnant sector trends and further widened its operational cushion.
According to the prevailing market view, margin resilience is a crucial differentiator in the hospitality sector, especially when most peers face inflation headwinds or cyclical cost pressures.
Higher profitability relative to the broader industry underlines bullish arguments that Abhotel benefits from strong cost controls and a nimble operational playbook.
Bulls will need to see ongoing margin improvement, rather than a one-off jump, to confidently price in long-term competitive advantages.
With a price-to-earnings ratio of 8.7x, Abhotel trades in line with similar peers and at a significant discount to the broader Japanese hospitality industry, which averages 23.1x. Its share price of ¥1,751 sits only slightly above the DCF fair value of ¥1,745.32.
The prevailing market view suggests this relative discount amplifies Abhotel’s appeal for value-seeking investors.
Well-above-sector-average profit margins combined with a modest valuation multiple challenge the idea that all hotel operators are equally exposed to cyclical swings, a stance seen in some more cautious perspectives.
As long as Abhotel sustains its margin gains without chasing valuation premiums, the current share price offers what many would consider a favorable risk-reward setup.


Zurletrectinib (ICP-723) demonstrated tolerability and promising antitumor activity among pediatric and adolescent patients with NTRK/ROS1-altered solid tumors in a phase 1/2 clinical trial (NCT04685226), according to a news release from the developers, InnoCare Pharma.1
Data were presented at the Congress of International Society of Pediatric Oncology (SIOP) 2025 in an oral presentation by Juan Wang of the Sun Yat-sen University Cancer Center in Guangzhou, China. As of July 31, 2025, the objective response rate (ORR) among patients treated with zurletrectinib was 90% as assessed by an independent review committee (IRC). Additionally, among patients who completed full efficacy evaluations, those resistant to first-generation TRK inhibitors all achieved partial responses.
Furthermore, no dose-limiting toxicities were observed with the investigational agent, and treatment-related adverse effects (TRAEs) were primarily grade 1 or 2.
Additionally, the recommended phase 2 dose (RP2D) was found to be 7.2 mg/m2 for pediatric patients and 8 mg/m2 for adolescent patients. At the RP2D, comparable exposure levels between pediatric or adolescent patients vs adult patients were shown for zurletrectinib.
Previous interim findings presented at the
Furthermore, the new drug application (NDA) for zurletrectinib as a treatment for patients with NTRK gene fusion-positive tumors was accepted by the Centre for Drug Evaluation (CDE) and was given priority review status in May 2025.3 The agency accepted the zurletrectinib NDA for review in the same patient population in April 2025.4
“Zurletrectinib has demonstrated outstanding efficacy and safety in adult, adolescent, and pediatric patients with tumors harboring NTRK fusion genes, bringing better treatment options for patients with solid tumors,” Jasmine Cui, PhD, co-founder, chairwoman, and chief executive officer of InnoCare, said in a news release on the NDA submission.4 “[InnoCare] is expanding the scope of its solid tumor pipelines through a combination of targeted therapies, immune-oncology approaches, and cutting-edge antibody drug conjugate [ADC] technology, looking forward to meeting the unmet needs of patients with solid tumors early.”
The multicenter, open-label phase 1/2 trial assigned patients with histopathologically confirmed, surgically unresectable, locally advanced or metastatic solid tumors who were 12 years of age and older to receive zurletrectinib as an oral tablet.5 The primary end points of the phase 1/2 study were safety and tolerability and maximum tolerated dose. Secondary end points included maximum concentration of zurletrectinib and ORR.
Patients were eligible for enrollment if they had at least 1 measurable lesion per RECIST v1.1 criteria, or for primary central nervous system tumors, per Response Assessment in Neuro-Oncology (RANO) or International Neuroblastomas Response Criteria (INRC) criteria; an ECOG performance status of 0 to 1 or Karnofsky or Lansky performance status of greater than 60; and a life expectancy of more than 3 months.
Exclusion criteria included having any concurrent malignancy within 5 years prior to first study dose, receipt of prior anti-cancer treatment within 28 days of the first study dose, or any major surgical procedures within 4 weeks or minor surgical procedure within 2 weeks of first study dose. Those with a history of allergic disease, severe drug allergy, or known hypersensitivity to any component of the tablet formulation were ineligible for study enrollment.
